Pfizer has paid around €45m ($51m) to purchase a 15% equity interest in Vivet Therapeutics, and will pay up to €560m that includes option exercise payment and certain
The post Pfizer secures option to buy Vivet Therapeutics in €560m deal appeared first on Pharmaceutical Business review.
Original Article: Pfizer secures option to buy Vivet Therapeutics in €560m deal